Results 61 to 70 of about 3,108,169 (356)

Regression of established subcutaneous B16-F10 murine melanoma tumors after gef gene therapy via the mitochondrial apoptotic pathway [PDF]

, 2010
ovel treatment modalities, including gene therapy, are needed for patients with advanced melanoma. We evaluated whether the gef gene, a suicide gene from Escherichia coli, had a significant cytotoxic impact on melanoma in vivo. First, we used a non-viral
Aranega, Antonia, Boulaiz, Houria, Carrillo, Esmeralda, Melguizo, Consolacion, Ortiz, Raul, Prados, Jose, Ramos, Juan Luis, Rodríguez Herva, Jose Juan, Segura, Ana   +8 more
core   +2 more sources

The Treatment of Advanced Melanoma: Therapeutic Update

International Journal of Molecular Sciences, 2022
Cutaneous melanoma is the main cause of death for skin cancer. The majority of patients with a diagnosis of melanoma have localized disease, which can be successfully treated with surgical treatment.
A. Villani, L. Potestio, G. Fabbrocini, G. Troncone, U. Malapelle, M. Scalvenzi   +5 more
semanticscholar   +1 more source

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

The Lancet Oncology, 2019
BACKGROUND Pembrolizumab improved progression-free survival and overall survival versus ipilimumab in patients with advanced melanoma and is now a standard of care in the first-line setting.
C. Robert, A. Ribas, J. Schachter, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. Blank, T. Petrella, O. Hamid, Shu-Chih Su, C. Krepler, N. Ibrahim, G. Long   +19 more
semanticscholar   +1 more source

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Clinical Cancer Research, 2021
Purpose: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated ...
P. Ascierto, B. Dréno, J. Larkin, A. Ribas, G. Liszkay, M. Maio, M. Mandalà, L. Demidov, D. Stroyakovskiy, L. Thomas, L. de la Cruz-Merino, V. Atkinson, C. Dutriaux, C. Garbe, J. Hsu, Surai Jones, Haocheng Li, E. McKenna, A. Voulgari, G. McArthur   +19 more
semanticscholar   +1 more source

Immunological backbone of uveal melanoma: is there a rationale for immunotherapy? [PDF]

, 2019
No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors.
Alessandra Cassano, Apte, Bill, Blom, Brigida Anna Maiorano, De Vries, Durie, Emilio Bria, Ericsson, Ernesto Rossi, Giampaolo Tortora, Gianluigi Petrone, Giovanni Schinzari, Guido Rindi, Ilaria Grazia Zizzari, Lagouros, Makitie, Maria Antonietta Blasi, Maria Grazia Sammarco, Marianna Nuti, Monica Maria Pagliara, Shaw, Sohn, Vincenzo Fiorentino, Whelchel   +24 more
core   +1 more source

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. [PDF]

, 2015
BackgroundPatients with BRAF mutation-positive advanced melanoma respond well to matched therapy with BRAF or MEK inhibitors, but often quickly develop resistance.MethodsTumor tissue from ten patients with advanced BRAF mutation-positive melanoma who ...
Cronin, Maureen T, Falchook, Gerald, Hong, David, Hwu, Patrick, Kim, Kevin B, Kurzrock, Razelle, Stephens, Philip J, Tsimberidou, Apostolia M, Wheler, Jennifer, Yelensky, Roman   +9 more
core   +3 more sources

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Annals of Oncology, 2019
Background Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein.
O. Hamid, C. Robert, A. Daud, F. Hodi, W. Hwu, R. Kefford, J. Wolchok, P. Hersey, P. Hersey, R. Joseph, J. Weber, R. Dronca, T. Mitchell, A. Patnaik, H. Zarour, A. Joshua, Qing Zhao, E. Jensen, S. Ahsan, N. Ibrahim, A. Ribas   +20 more
semanticscholar   +1 more source

Advances in management of melanoma [PDF]

Australian and New Zealand Journal of Medicine, 1999
It is clear from the above that the sentinel node technique and assessment of circulating melanoma cells has provided important additional methods for staging and assessment of prognosis of patients with melanoma. Cure of the disease still depends on good quality surgery and implementation of quality control measures to ensure the adequacy of surgical ...
openaire   +2 more sources

Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER–Medicare database

Therapeutic Advances in Drug Safety, 2021
Background: The use of anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) therapy (ipilimumab) and anti-programmed cell-death 1 (anti-PD1) agents (nivolumab and pembrolizumab) in advanced melanoma have been associated with immune-related adverse events ...
Abdulaali R. Almutairi, Marion Slack, Brian L. Erstad, Ali McBride, Ivo Abraham   +4 more
doaj   +1 more source